Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dey DuoNeb

Executive Summary

Albuterol and ipratropium dual-therapy nebulizer is approved for "the treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients requiring more than one bronchodilator." FDA approved the inhalation solution of 3.0 mg albuterol and .5 mg ipratropium/3 mL March 21. A 12-week, 863-patient trial comparing DuoNeb with albuterol and ipratropium alone demonstrated that DuoNeb contributed to the improvement in pulmonary function "especially during the first 4 to 5 hours after dosing and that DuoNeb was significantly more effective than albuterol sulfate or ipratropium bromide alone," labeling states
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS037580

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel